Arrowhead Research Corp. (Nasdaq: ARWR) completed enrollment of the first cohort in a Phase 2c trial of its chronic hepatitis B treatment ARC-520. The stock price soared $2.04 to $18.46.
Arrowhead Research Completes Enrollment
April 01, 2014 at 13:24 PM EDT
